Skip to content

Focal Medical Provides Business Update

Ness Bermingham, Ph.D. Khosla Ventures partner and Intellia Therapeutics founder, joins Board.  Advance of IOP cisplatin for locally recurrent oral cavity cancer into formal development. Cary, North Carolina, January 30, 2024 — Focal Medical, Inc., (“Focal”) a Khosla Ventures backed…

Read more

PRESS RELEASE: Focal Medical Receives FDA Clearance to Initiate Phase 1b Clinical Trial of ACT-IOP-003, a Targeted Therapeutic Product in Development for Pancreatic Cancer

ACT-IOP-003 is an implantable iontophoretic product designed to safely achieve high concentration of gemcitabine in the pancreas, via non-circulatory pathways and with little to no systemic drug exposure or associated toxicity. Demonstrated dramatic results in an orthotopic patient-derived xenograft murine…

Read more

Focal Medical Successfully Completes Development of a Laparoscopic Surgical Implantation Technique for Targeted Therapeutic System

Developed a laparoscopic surgical technique to enable the minimally invasive implantation of ACT-IOP-003 device onto the pancreas. ACT-IOP-003, Focal Medical’s targeted therapeutic product, is designed to safely achieve a high concentration of chemotherapeutic in the target organ, via non-circulatory pathways,…

Read more

Initiation of Canine Oral Cancer Study

Trial & Enrollment Details   Cary, NC and Roanoke, VA, May 04, 2023 — Focal Medical, Inc., a privately held, biopharmaceutical company developing novel therapeutic products based on its innovative local drug delivery technology platform today announced the initiation of…

Read more
Back To Top